DBV 1502
Alternative Names: DBV-1502; Viaskin® EggLatest Information Update: 12 Apr 2024
At a glance
- Originator DBV Technologies
- Class Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Food hypersensitivity
Most Recent Events
- 12 Apr 2024 DBV 1502 is still in preclinical phase for Food hypersensitivity in the France (Topical, Patch) (DBV Technologies pipeline, April 2024)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Allergy in France (Topical, Patch)
- 03 Jan 2022 DBV 1502 is still in preclinical studies for Food hypersensitivity in the France (DBV Technologies pipeline, January 2022)